🔗 Share this article The Global Health Body Sounds Warning Over Acute Scarcity of Obesity Injections Fewer than a tenth of patients eligible to benefit from obesity jabs including Wegovy can access them, caution the WHO as it publishes its first advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to these injectable treatments. Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "The new guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key hurdles to widespread access to the injections that can assist patients in reducing substantial weight, says the body. Skinny Jab Shortage Even in the present best projected outlook, the supply of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, per the WHO. The advice urges nations and manufacturers to increase availability, by strategies including patent sharing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is due to expire in a number of nations in 2026. How Obesity Jabs Operate The injections imitate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so individuals eat less. Individuals typically see weight reduction after several weeks of beginning the regular doses. Research indicates people may put most of the weight back on within a year of discontinuing the treatment, when their typical food cravings resume. Being carrying excess weight increases your chance for contracting diseases, like type 2 diabetes, heart disease, stroke, and some cancers. Obesity affects individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
Fewer than a tenth of patients eligible to benefit from obesity jabs including Wegovy can access them, caution the WHO as it publishes its first advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to these injectable treatments. Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "The new guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key hurdles to widespread access to the injections that can assist patients in reducing substantial weight, says the body. Skinny Jab Shortage Even in the present best projected outlook, the supply of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, per the WHO. The advice urges nations and manufacturers to increase availability, by strategies including patent sharing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is due to expire in a number of nations in 2026. How Obesity Jabs Operate The injections imitate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so individuals eat less. Individuals typically see weight reduction after several weeks of beginning the regular doses. Research indicates people may put most of the weight back on within a year of discontinuing the treatment, when their typical food cravings resume. Being carrying excess weight increases your chance for contracting diseases, like type 2 diabetes, heart disease, stroke, and some cancers. Obesity affects individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.